India, April 27 -- India's largest drugmaker, Sun Pharmaceutical Industries Ltd, on Monday declared that it is acquiring the US-based healthcare company Organon & Co in a deal worth USD 11.75 billion. This saw the company's shares surge hoover 7% on the stock market. The deal is priced at USD 14 per share in an all-cash transaction, and has witnessed the company's standing in women's health and bio-similars surge exorbitantly. The transaction has been approved by the Boards of Directors of both Sun Pharma and Organon and is subject to customary closing conditions, including receipt of required regulatory approvals and approval by Organon stockholders, according to a press release. 

The New Jersey-based company Organon's portfolio in...